Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-pa... by Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba

Get full text

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel by Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba

Get full text

Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study... by Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, Taiga Otsuka, Yuki Sonoda, Takuya Honda, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Hiroki Taguchi, Kengo Tsuneyoshi, Toshihiro Fujita, Takahiro Sakae, Yasunori Kawaguchi, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301) by Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Azusa Komori, Kazuo Nishikawa, Satoshi Otsu, Ayumu Hosokawa, Hisanobu Oda, Tatsunori Sakai, Shuji Arita, Machiko Kawahira, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel by Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer by Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Junichi Nakazawa, Takeshi Hori, Taro Shibuki, Shiho Arima, Akio Ido, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Kenji Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text